Abstract
The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson’s disease (PD) and Alzheimer’s diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets.
In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).
Keywords: Genome wide association study (GWAS), neurodegenerative diseases, pharmacogenomics, psychiatric disorders.
Current Molecular Medicine
Title:The Applications of Pharmacogenomics to Neurological Disorders
Volume: 14 Issue: 7
Author(s): C. Gilman, C. McSweeney and Y. Mao
Affiliation:
Keywords: Genome wide association study (GWAS), neurodegenerative diseases, pharmacogenomics, psychiatric disorders.
Abstract: The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson’s disease (PD) and Alzheimer’s diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets.
In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).
Export Options
About this article
Cite this article as:
Gilman C., McSweeney C. and Mao Y., The Applications of Pharmacogenomics to Neurological Disorders, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811115900
DOI https://dx.doi.org/10.2174/1566524014666140811115900 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Fenofibrate and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Patent Ductus Arteriosus in Extreme Prematurity: Role of Echocar-diography and Other Imaging Techniques
Current Pediatric Reviews Investigating the Relationship the Severity of Coronary Artery Disease with Serum Levels of Vitamin D in Men after Eliminating the Effect of Diet
Current Nutrition & Food Science IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets Clinical Utility of Microarrays: Current Status, Existing Challenges and Future Outlook
Current Genomics Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets The Impact of Dietary Habits and Nutritional Deficiencies in Urban African Patients Living with Heart Failure in Soweto, South Africa – A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Respiratory Viruses, Eosinophil Activation, and Early Allergen Sensitization - Early Life Predictors of Persistent Wheezing and Asthma
Current Pediatric Reviews Fc-Independent Phagocytosis: Implications for Intravenous IgG Therapy in Immune Thrombocytopenia
Cardiovascular & Hematological Disorders-Drug Targets Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry